共 50 条
Recent advances in zeolitic imidazolate frameworks as drug delivery systems for cancer therapy
被引:0
|作者:
Wang, Yuhan
[1
,2
]
Tang, Yixin
[1
]
Guo, Lei
[1
]
Yang, Xi
[1
]
Wu, Shanli
[1
]
Yue, Ying
[2
]
Xu, Caina
[1
]
机构:
[1] Jilin Univ, Coll Basic Med Sci, Dept Biochem, Changchun 130021, Peoples R China
[2] First Hosp Jilin Univ, Dept Gynecol Oncol, Changchun 130021, Peoples R China
基金:
中国国家自然科学基金;
关键词:
Metal-organic frameworks (MOFs);
Zeolitic imidazolate frameworks;
(ZIF-8);
ZIF-based nanoparticles;
Drug delivery;
Cancer treatment;
METAL-ORGANIC FRAMEWORKS;
CELL-PENETRATING PEPTIDES;
ONE-POT SYNTHESIS;
NEUROPEPTIDE-Y;
FAVORABLE BIOCOMPATIBILITY;
NANOPARTICLES;
ZIF-8;
SIZE;
NANOCARRIERS;
NANOPLATFORM;
D O I:
10.1016/j.ajps.2025.101017
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Biological nanotechnologies based on functional nanoplatforms have synergistically catalyzed the emergence of cancer therapies. As a subtype of metal-organic frameworks (MOFs), zeolitic imidazolate frameworks (ZIFs) have exploded in popularity in the field of biomaterials as excellent protective materials with the advantages of conformational flexibility, thermal and chemical stability, and functional controllability. With these superior properties, the applications of ZIF-based materials in combination with various therapies for cancer treatment have grown rapidly in recent years, showing remarkable achievements and great potential. This review elucidates the recent advancements in the use of ZIFs as drug delivery agents for cancer therapy. The structures, synthesis methods, properties, and various modifiers of ZIFs used in oncotherapy are presented. Recent advances in the application of ZIF-based nanoparticles as single or combination tumor treatments are reviewed. Furthermore, the future prospects, potential limitations, and challenges of the application of ZIF-based nanomaterials in cancer treatment are discussed. We except to fully explore the potential of ZIF-based materials to present a clear outline for their application as an effective cancer treatment to help them achieve early clinical application. (c) 2025 Shenyang Pharmaceutical University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:26
相关论文